RxDoctor Payments Data

Kevin McGrath, MD

Internal Medicine · Kilmarnock, VANPI 1699834978

Payments from drug & device makers

$2,135in general payments, 2019–2025

Across 126 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$434
  • Pfizer$353
  • Amgen$332
  • AbbVie$167
  • AstraZeneca$131
  • Radius Health, Inc.$67
  • plus $651 from 17 others

What the payments were for

  • Food & beverage$2,135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,135 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$208,607
Medicare patients
481
Services billed
2,918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban164$144,737
OzempicSemaglutide39$58,888
XareltoRivaroxaban45$35,932
Teriparatide18$33,543
JardianceEmpagliflozin23$32,237
VascepaIcosapent Ethyl27$19,688
LivaloPitavastatin Calcium32$14,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,704
MultaqDronedarone Hcl11$8,830
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$4,595
PaxlovidNirmatrelvir/Ritonavir23$4,287
Atorvastatin Calcium274$4,119
Wixela InhubFluticasone Propion/Salmeterol15$3,488
Potassium Chloride27$2,873
Metoprolol Succinate185$2,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$353$149,024187 claims
Novo NordiskOzempic$434$58,88839 claims
Johnson & JohnsonXarelto$61$35,93245 claims
GSKTrelegy Ellipta$62$10,70413 claims
AbbVieSynthroid$167$1,12239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Kilmarnock

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →